Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70-Targeted CAR-T in Advanced CD70-Positive Malignant Solid Tumors
NCT07181720Phase 1Suspended
- Sponsor
- Chongqing Precision Biotech
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD70 CAR-T cells in renal cell carcinoma (RCC), lung cancer, anaplastic thyroid carcinoma (ATC) and 3 more (3 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Safety and Tolerability at 1 month and Recommended dose and infusion regimen at 1 month. Started Sep 2025; status: suspended.
02
Drugs
CD70 CAR-T cells
03
Conditions
renal cell carcinoma (RCC)lung canceranaplastic thyroid carcinoma (ATC)ovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT07181720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181720.